GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aclaris Therapeutics Inc (LTS:0H8T) » Definitions » Policyholder Funds

Aclaris Therapeutics (LTS:0H8T) Policyholder Funds


View and export this data going back to 2018. Start your Free Trial

What is Aclaris Therapeutics Policyholder Funds?

Policyholder Funds only applies to insurance companies.


Aclaris Therapeutics Business Description

Traded in Other Exchanges
Address
701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.